Overview

Folinic acid, also known as leucovorin or 5-formyltetrahydrofolate, is a reduced and metabolically active form of folic acid that does not require enzymatic reduction by dihydrofolate reductase (DHFR) to enter the folate cycle. This property makes it clinically invaluable as a "rescue" agent following high-dose methotrexate chemotherapy, where it restores folate-dependent biosynthetic pathways in healthy cells while preserving the drug's anti-tumor effects.

Beyond its established role in oncology, folinic acid supports critical one-carbon metabolism reactions including DNA synthesis, amino acid interconversion, and methylation processes. Unlike folic acid, it can be utilized directly by cells regardless of polymorphisms in the MTHFR gene, making it a preferred supplemental form for individuals with impaired folate metabolism. It has been studied in the context of neural tube defect prevention, neuropsychiatric conditions, and cerebral folate deficiency syndromes.

Research in autism spectrum disorder has generated particular interest, with some clinical trials suggesting that folinic acid supplementation may improve verbal communication in children with identified folate receptor autoantibodies. It is also used adjunctively with 5-fluorouracil in colorectal cancer protocols, where it enhances the cytotoxic effect of the chemotherapy agent by stabilizing its binding to thymidylate synthase.

Mechanism of Action

Reduced Folate Bypass Mechanism

Folinic acid (5-formyltetrahydrofolate, leucovorin) is a metabolically active reduced form of folic acid that bypasses the enzymatic step catalyzed by dihydrofolate reductase (DHFR). Unlike folic acid, it does not require DHFR-mediated reduction to enter the folate cycle, making it critical as a "rescue" agent after methotrexate therapy, which inhibits DHFR (PMID: 27599753).

One-Carbon Transfer Reactions

Once administered, folinic acid is rapidly converted to 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase and subsequently to 5-methyltetrahydrofolate (5-MTHF) by methylenetetrahydrofolate reductase (MTHFR). These folate coenzymes serve as one-carbon donors for critical biosynthetic reactions including thymidylate synthesis (via thymidylate synthase, essential for DNA replication), purine biosynthesis (supplying C2 and C8 of the purine ring), and methionine regeneration from homocysteine via methionine synthase (PMID: 22419553).

Synergy with 5-Fluorouracil

In oncology, folinic acid potentiates the cytotoxicity of 5-fluorouracil (5-FU) by stabilizing the ternary complex of 5-FdUMP, thymidylate synthase, and 5,10-methylenetetrahydrofolate. This enhanced inhibition of thymidylate synthase depletes intracellular dTMP pools, causing thymineless death in rapidly dividing cancer cells (PMID: 8898171).

Methylation & Neurotransmitter Support

By replenishing tetrahydrofolate pools, folinic acid supports the methionine-SAMe cycle, facilitating S-adenosylmethionine (SAMe)-dependent methylation of DNA, histones, neurotransmitters, and phospholipids. This is particularly relevant in individuals with MTHFR polymorphisms or cerebral folate deficiency, where folinic acid can cross the blood-brain barrier via folate receptor alpha (PMID: 19924226).

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Folinic Acid (Leucovorin)

Common Side Effects

• Gastrointestinal: nausea, vomiting, diarrhea, and stomatitis (especially during 5-FU rescue protocols)
• Skin rash, urticaria, or pruritus in approximately 2–5% of patients
• Insomnia and agitation reported with high-dose IV administration
• Fever and malaise, particularly in chemotherapy combination regimens
• Injection site reactions (pain, erythema, induration) with IM or IV administration

Serious Adverse Effects

• Seizures: reported in patients receiving high-dose IV leucovorin, particularly those with pre-existing CNS conditions or receiving intrathecal methotrexate
• Severe hypersensitivity: anaphylaxis, angioedema, and Stevens-Johnson syndrome reported rarely
• Enhanced 5-fluorouracil toxicity: when used as a chemotherapy potentiator, folinic acid significantly increases GI toxicity (severe diarrhea, mucositis) and myelosuppression
• Masking of B12 deficiency: may correct megaloblastic anemia while allowing irreversible neurological damage from untreated B12 deficiency to progress
• Thrombocytopenia and leukopenia when combined with antifolate chemotherapy
• Rare reports of encephalopathy at very high parenteral doses

Contraindications

• Pernicious anemia or undiagnosed B12 deficiency: leucovorin may mask hematologic signs while neurological damage progresses
• Known hypersensitivity to folinic acid or any formulation component
• Intrathecal administration is contraindicated (neurotoxic by this route)
• Should not be used to counteract the effects of methotrexate in the treatment of meningeal leukemia

Drug Interactions

• 5-Fluorouracil (5-FU): intentionally combined in oncology, but dramatically increases 5-FU toxicity (GI, hematologic); requires careful dosing and monitoring
• Methotrexate: used as rescue agent; timing is critical — delayed leucovorin administration reduces efficacy of rescue
• Trimethoprim-sulfamethoxazole: folinic acid may reduce antimicrobial efficacy by providing folate to bacteria; folic acid (not folinic acid) is preferred for folate supplementation during TMP-SMX therapy
• Phenobarbital, phenytoin, primidone: folinic acid may reduce anticonvulsant plasma levels, increasing seizure risk
• Capecitabine: similar interaction as 5-FU; enhanced toxicity profile
• Glucarpidase (Voraxaze): do not administer leucovorin within 2 hours of glucarpidase

Population-Specific Considerations

• Pregnant women: leucovorin is FDA Category C; used when benefit outweighs risk, primarily in methotrexate rescue during ectopic pregnancy treatment
• Breastfeeding: folate is secreted in breast milk; high-dose leucovorin should be used with caution; discuss with oncologist if on chemotherapy
• Pediatric patients: dosing for methotrexate rescue is weight-based; monitor renal function and methotrexate levels closely
• Elderly: increased susceptibility to enhanced 5-FU toxicity; dose reductions often required
• Renal impairment: delayed methotrexate clearance may require extended leucovorin rescue; monitor serum methotrexate levels until below 0.05 μM
• Hepatic impairment: metabolism may be altered; monitor for toxicity signs with combination chemotherapy

Pharmacokinetic Profile